Enlivex Therapeutics Stock Net Income
| ENLV Stock | USD 1.40 0.08 5.41% |
Enlivex Therapeutics fundamentals help investors to digest information that contributes to Enlivex Therapeutics' financial success or failures. It also enables traders to predict the movement of Enlivex Stock. The fundamental analysis module provides a way to measure Enlivex Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Enlivex Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -29.1 M | -27.6 M | |
| Net Loss | -27.2 M | -25.8 M | |
| Net Loss | -28 M | -26.6 M | |
| Net Loss | (1.56) | (1.64) | |
| Net Income Per E B T | 1.23 | 0.83 |
Enlivex | Net Income |
Enlivex Therapeutics Company Net Income Analysis
Enlivex Therapeutics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Enlivex Therapeutics Net Income | (29.07 M) |
Most of Enlivex Therapeutics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Enlivex Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enlivex Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Enlivex Therapeutics is extremely important. It helps to project a fair market value of Enlivex Stock properly, considering its historical fundamentals such as Net Income. Since Enlivex Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Enlivex Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Enlivex Therapeutics' interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Enlivex Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Enlivex Therapeutics reported net income of (29.07 Million). This is 108.52% lower than that of the Software sector and 141.5% lower than that of the Information Technology industry. The net income for all United States stocks is 105.09% higher than that of the company.
Enlivex Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Enlivex Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Enlivex Therapeutics could also be used in its relative valuation, which is a method of valuing Enlivex Therapeutics by comparing valuation metrics of similar companies.Enlivex Therapeutics is currently under evaluation in net income category among related companies.
Enlivex Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Enlivex Therapeutics from analyzing Enlivex Therapeutics' financial statements. These drivers represent accounts that assess Enlivex Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Enlivex Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 72.6M | 111.0M | 111.6M | 72.5M | 50.2M | 50.2M | |
| Enterprise Value | 68.7M | 105.5M | 101.0M | 29.5M | 50.3M | 41.9M |
Enlivex Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Enlivex Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Enlivex Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Enlivex Therapeutics' value.| Shares | Advisor Group Holdings, Inc. | 2023-12-31 | 400 | Bank Of America Corp | 2023-12-31 | 266 | Jpmorgan Chase & Co | 2023-12-31 | 237 | Advisory Services Network, Llc | 2023-12-31 | 43.0 | Qube Research & Technologies | 2023-12-31 | 1.0 | Goldman Sachs Group Inc | 2023-09-30 | 0.0 | Srs Capital Advisors Inc | 2023-09-30 | 0.0 | Susquehanna International Group Ltd | 2023-12-31 | 0.0 | Simplex Trading, Llc | 2023-09-30 | 0.0 | Renaissance Technologies Corp | 2023-12-31 | 62.1 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 44.5 K |
Enlivex Fundamentals
| Return On Equity | -0.67 | ||||
| Return On Asset | -0.3 | ||||
| Current Valuation | 679.9 K | ||||
| Shares Outstanding | 18.6 M | ||||
| Shares Owned By Insiders | 11.80 % | ||||
| Shares Owned By Institutions | 8.93 % | ||||
| Number Of Shares Shorted | 236.38 K | ||||
| Price To Earning | (11.97) X | ||||
| Price To Book | 0.76 X | ||||
| EBITDA | (24.09 M) | ||||
| Net Income | (29.07 M) | ||||
| Cash And Equivalents | 62.48 M | ||||
| Cash Per Share | 3.40 X | ||||
| Total Debt | 1.03 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 15.44 X | ||||
| Book Value Per Share | 1.62 X | ||||
| Cash Flow From Operations | (23.52 M) | ||||
| Short Ratio | 2.38 X | ||||
| Earnings Per Share | (1.47) X | ||||
| Target Price | 7.0 | ||||
| Beta | 1.06 | ||||
| Market Capitalization | 26.97 M | ||||
| Total Asset | 36.83 M | ||||
| Retained Earnings | (112.09 M) | ||||
| Working Capital | 45.72 M | ||||
| Current Asset | 6 M | ||||
| Current Liabilities | 671.32 K | ||||
| Net Asset | 36.83 M |
About Enlivex Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Enlivex Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Enlivex Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Enlivex Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Enlivex Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Enlivex Therapeutics' short interest history, or implied volatility extrapolated from Enlivex Therapeutics options trading.
Pair Trading with Enlivex Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Enlivex Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enlivex Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Enlivex Stock
| 0.5 | SABR | Sabre Corpo Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to Enlivex Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Enlivex Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Enlivex Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Enlivex Therapeutics to buy it.
The correlation of Enlivex Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Enlivex Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Enlivex Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Enlivex Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Enlivex Therapeutics Piotroski F Score and Enlivex Therapeutics Altman Z Score analysis. For more information on how to buy Enlivex Stock please use our How to Invest in Enlivex Therapeutics guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Complementary Tools for Enlivex Stock analysis
When running Enlivex Therapeutics' price analysis, check to measure Enlivex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enlivex Therapeutics is operating at the current time. Most of Enlivex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Enlivex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enlivex Therapeutics' price. Additionally, you may evaluate how the addition of Enlivex Therapeutics to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |
Is Enlivex Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enlivex Therapeutics. If investors know Enlivex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enlivex Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.47) | Return On Assets (0.30) | Return On Equity (0.67) |
The market value of Enlivex Therapeutics is measured differently than its book value, which is the value of Enlivex that is recorded on the company's balance sheet. Investors also form their own opinion of Enlivex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Enlivex Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enlivex Therapeutics' market value can be influenced by many factors that don't directly affect Enlivex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enlivex Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enlivex Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enlivex Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.